Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P.T. Heath, R. Booy, H. Azzopardi, M.P.E. Slack, J. Bowen-Morris, H. Griffiths, et al.
Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdon.
JAMA, 284 (2000), pp. 2334-2340
[2.]
K. Pushparajah, P. Ramnarayan, A. Maniyar, R. Paget, J. Britto.
Continued threat of Haemophilus influenzae type B disease in the UK.
Lancet, 361 (2003), pp. 90
[3.]
C.L. Trotter, M.E. Ramsay.
Slack MPE. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign.
Comm Dis Public Health, 6 (2003), pp. 55-58
[4.]
D. Garner, V. Weston.
Effectiveness of vaccination for Haemophilus influenzae type b.
Lancet, 361 (2003), pp. 395-396
[5.]
M. Steinhoff, D. Goldblatt.
Conjugate Hib vaccines.
Lancet, 361 (2003), pp. 360-361
[6.]
J. McVernon, P. Heath.
Re-inforcement of Hib inmunisation requiered.
Comm Dis Public Health, 6 (2003), pp. 2
[7.]
J. McVernon, N. Andrews, M.P.E. Slack, M.E. Ramsay.
Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis.
Lancet, 361 (2003), pp. 1521-1523
[8.]
G.T. Rijkers, P. Vermeer-de Bondt, L. Spanjaard, M.A. Breukels.
Sanders EAM. Return of Haemophilus influenzae type b infections.
Lancet, 361 (2003), pp. 1563-1564
[9.]
J. Campos, J.A. Sáez-Nieto.
Gram negative infections: Haemophilus and other clinically relevant gram negative coccobacilli.
Laboratory Diagnosis of bacterial Infections, pp. 557-580
[10.]
CDC.
Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000.
MMWR, 51 (2002), pp. 234-237
[11.]
C. Beni, J.A. Cayla, J.M. Jansa, R. Maldonado, H. Panella, L. Rajmil, et al.
Enfermedad invasiva por Haemophilus influenzae tipo b y enfermedad meningocócica: incidencia y características en Barcelona, 1994-1995.
Med Clin (Barc), 112 (1999), pp. 1-4
[12.]
J. Díez-Domingo, I. Pereiro, A. Morant, C. Gimeno, M. San-Martín, A. González.
Group for the Study of Invasive Diseases. Impact of non-routine vaccination on the incidence of invasive Haemophilus influenzae type b (Hib) disease: Experience in the autonomous region of Valencia, Spain.
J Infect, 42 (2001), pp. 257-260
[13.]
J. Campos, S. García-Tornel, J.M. Gairi.
Multiply resistant Haemophilus influenzae type b causing meningitis: Comparative clinical and laboratory study.
J Pediatr, 108 (1986), pp. 897-902
[14.]
H. Peltola.
Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates.
Clin Microbiol Rev, 13 (2000), pp. 302-317
[15.]
P.T. Heath, R. Booy, H. Griffiths, E. Clutterbuck, H. Azzopardi, Slack, MPE, et al.
Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood.
Clin Infec Dis, 31 (2000), pp. 972-980
[16.]
J. Campos, B. Aracil, F. Román, M. Pérez-Vázquez.
and the Spanish collaborative group for Hib vaccine failures. Molecular epidemiology of Haemophilus influenzae type b isolated from clinical cases of conjugate-vaccine failures in children.
J Clin Microbiol, 41 (2003), pp. 3915-3918
[17.]
C.L. Trotter, J. McVernon, N.J. Andrews, M. Burrage, Ramsay, ME.
Antibody to Haemophilus influenzae type b after routine and catch-up vaccination.
Lancet, 361 (2003), pp. 1523-1524
[18.]
J. Eskola, R. Ölander, T. Hovi, L. Litmanen, S. Peltola.
Käyhty. Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
Lancet, 348 (1996), pp. 1688-1692
[19.]
F. Bell, P. Heath, F. Shackley, J. MacLennan, N. Shearstone, L. Diggle, et al.
Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T).
Vaccine, 16 (1998), pp. 637-642
[20.]
P.T. Heath, M.E. Ramsay.
Haemophilus influenzae type b vaccine-booster campaign.
BMJ, 326 (2003), pp. 1158-1159
[21.]
R. Dagan, J. Eskola, C. Leclerc, O. Leroy.
Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.
Infect Immun, 66 (1998), pp. 2093-2098
[22.]
M.D. Decker.
Principles of pediatric combination vaccines and practical issues related to use in clinical practice.
Pediatr Infect Dis J, 20 (2001), pp. S10-S18
[23.]
F.E. Andre.
Development and clinical application of new polyvalent combined paediatric vaccines.
Vaccine, 17 (1999), pp. 1620-1627
[24.]
Comité Asesor de Vacunas de la Asociación Española de Pediatría.
Calendario vacunal de la Asociación Española de Pediatría 2003.
An Pediatr (Barc), 58 (2003), pp. 257-262
[25.]
D.P. Greeberg, S. Feldman.
Vaccine interchangeability.
Clin Pediatr, 42 (2003), pp. 93-99
[26.]
M.E. Ramsay, J. McVernon, N.J. Andrews, M.P. Slack.
Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method.
J Infect Dis, 188 (2003), pp. 481-485
Copyright © 2003. Asociación Española de Pediatría
